Alaunos Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $5,000 | $10,000 | $5,000 | $2.9M | $398,000 |
| Operating income | -$4.2M | -$4.8M | -$34.3M | -$35.1M | -$77.5M |
| Operating expenses | $4.2M | $4.8M | $34.3M | $38.0M | $77.9M |
| Cash from operations | -$2.9M | -$5.0M | -$30.1M | -$29.2M | -$61.5M |
| Capital expenditure | $98,000 | $0 | $197,000 | $216,000 | $3.3M |
| Free cash flow | -$3.0M | -$5.0M | -$30.3M | -$29.4M | -$64.8M |
| Share repurchases | — | — | $0 | $45,000 | $0 |
| Impairments | — | $0 | $4.8M | $0 | $740,000 |
| Total assets | $3.0M | $2.8M | $8.3M | $64.9M | $94.9M |
| Total liabilities | $813,000 | $692,000 | $2.0M | $26.4M | $36.8M |
| Total debt | — | — | — | $16.8M | $24.1M |
Shares outstanding 24.4M · Free float 57.2%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.